Northern Trust Corp Purchases 145,205 Shares of Pacira BioSciences, Inc. (NASDAQ:PCRX)

Northern Trust Corp lifted its position in shares of Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) by 30.8% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 616,891 shares of the company's stock after acquiring an additional 145,205 shares during the period. Northern Trust Corp owned approximately 1.34% of Pacira BioSciences worth $11,622,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds also recently made changes to their positions in the company. ExodusPoint Capital Management LP lifted its holdings in Pacira BioSciences by 232.6% during the fourth quarter. ExodusPoint Capital Management LP now owns 212,824 shares of the company's stock valued at $4,010,000 after purchasing an additional 148,842 shares in the last quarter. Norges Bank bought a new position in Pacira BioSciences during the 4th quarter valued at about $2,405,000. Natixis purchased a new stake in Pacira BioSciences in the 4th quarter valued at about $1,738,000. Charles Schwab Investment Management Inc. boosted its stake in shares of Pacira BioSciences by 16.3% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 502,204 shares of the company's stock valued at $9,462,000 after purchasing an additional 70,307 shares in the last quarter. Finally, Impax Asset Management Group plc boosted its stake in shares of Pacira BioSciences by 14.8% during the fourth quarter. Impax Asset Management Group plc now owns 540,027 shares of the company's stock valued at $10,174,000 after purchasing an additional 69,424 shares in the last quarter. Institutional investors own 99.73% of the company's stock.

Pacira BioSciences Stock Down 0.3%

Shares of NASDAQ PCRX traded down $0.07 during trading hours on Thursday, hitting $26.07. The stock had a trading volume of 616,356 shares, compared to its average volume of 972,136. The company has a market capitalization of $1.21 billion, a P/E ratio of -12.84 and a beta of 0.56. The firm's 50-day moving average price is $25.17 and its two-hundred day moving average price is $22.63. Pacira BioSciences, Inc. has a 52 week low of $11.16 and a 52 week high of $31.64. The company has a debt-to-equity ratio of 0.51, a quick ratio of 1.89 and a current ratio of 2.25.

Wall Street Analysts Forecast Growth

Several research firms recently commented on PCRX. Barclays raised their price target on shares of Pacira BioSciences from $17.00 to $24.00 and gave the company an "overweight" rating in a research report on Friday, February 28th. HC Wainwright increased their price target on shares of Pacira BioSciences from $48.00 to $65.00 and gave the stock a "buy" rating in a research note on Tuesday, April 8th. Needham & Company LLC dropped their target price on shares of Pacira BioSciences from $32.00 to $30.00 and set a "buy" rating for the company in a report on Friday, May 9th. Finally, Truist Financial raised shares of Pacira BioSciences from a "sell" rating to a "hold" rating and raised their target price for the stock from $8.00 to $25.00 in a research report on Thursday, January 30th. One research analyst has rated the stock with a sell rating, four have issued a hold rating and five have assigned a buy rating to the company's stock. According to data from MarketBeat, the stock presently has an average rating of "Hold" and a consensus price target of $26.44.

Pacira BioSciences Profile

Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients' journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.